We Offer Worldwide Shipping
Login Wishlist

2-Deacetoxy-taxinine J


  • Brand : BIOFRON

  • Catalogue Number : AV-B04147

  • Specification : 95%

  • CAS number : 119347-14-7

  • Formula : C37H46O10

  • Molecular Weight : 650.76

  • PUBCHEM ID : 14192854

  • Volume : 5mg

Available on backorder

Checkout Bulk Order?

Catalogue Number


Analysis Method






Molecular Weight




Botanical Source

Structure Type



Standards;Natural Pytochemical;API




(5α,7β,9α,10β,13α)-7,9,10,13-tetrakis(acetyloxy)taxa-4(20),11-dien-5-yl (2E)-3-phenylprop-2-enoate/2-Propenoic acid, 3-phenyl-, (1S,3S,4aR,6R,8S,11R,12R,12aS)-1,8,11,12-tetrakis(acetyloxy)-1,2,3,4,4a,5,6,7,8,11,12,12a-dodecahydro-9,12a,13,13-tetramethyl-4-methylene-6,10-methanobenzocyclodecen-3-yl ester, (2E)-/(5α,7β,9α,10β,13α)-7,9,10,13-Tetraacetoxytaxa-4(20),11-dien-5-yl (2E)-3-phenylacrylate


[(1R,3R,5S,7S,8S,9R,10R,13S)-7,9,10,13-tetraacetyloxy-8,12,15,15-tetramethyl-4-methylidene-5-tricyclo[,8]pentadec-11-enyl] (E)-3-phenylprop-2-enoate


1.2±0.1 g/cm3


Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

273.8±31.5 °C

Boiling Point

673.8±55.0 °C at 760 mmHg

Melting Point




InChl Key


WGK Germany


HS Code Reference


Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:119347-14-7) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.




To examine factors associated with 0? to 7?day admission after outpatient surgery in high?volume specialties: general surgery, orthopedics, urology, ear/nose/throat, and podiatry.

Study Design
We calculated rates and assessed diagnosis codes for 0? to 7?day admission after outpatient surgery for Centers for Medicare and Medicaid Services (CMS) and Veterans Health Administration (VA) dually enrolled patients age 65 and older. We also estimated separate multilevel logistic regression models to compare patient, procedure, and facility characteristics associated with postoperative admission.

Data Collection
2011-2013 surgical encounter data from the VA Corporate Data Warehouse; geographic data from the Area Health Resources File; CMS enrollment and hospital admission data.

Principal Findings
Among 63,585 outpatient surgeries in 124 facilities, 0? to 7?day admission rates ranged from 5 percent (podiatry) to 28 percent (urology); nearly 66 percent of the admissions occurred on the day of surgery. Only 97 admissions were detected in the CMS data (1 percent). Surgical complications were diagnosed in 4 percent of admissions. Procedure complexity, measured by relative value units or anesthesia risk score, was associated with admission across all specialties.

As many as 20 percent of VA outpatient surgeries result in an admission. Complex procedures are more likely to be followed by admission, but more evidence is required to determine how many of these reflect potential safety or quality problems.


Ambulatory surgery, adverse event detection, readmissions, health services research, Veterans Health Administration


Factors Associated with Hospital Admission after Outpatient Surgery in the Veterans Health Administration


Hillary J. Mull, Ph.D., M.P.P.,corresponding author 1 , 2 Amy K. Rosen, Ph.D., 1 , 2 William J. O'Brien, M.S., 1 Nathalie McIntosh, Ph.D., 3 Aaron Legler, M.P.H., 4 Mary T. Hawn, M.D., M.P.H., 5 , 6 Kamal M. F. Itani, M.D., 2 , 7 , 8 and Steven D. Pizer, Ph.D. 4 , 9

Publish date

2018 Oct;




Beginning with precursor lesions, aberrant DNA methylation marks the entire spectrum of prostate cancer progression. We mapped the global DNA methylation patterns in select prostate tissues and cell lines using MethylPlex-next-generation sequencing (M-NGS). Hidden Markov model-based next-generation sequence analysis identified ∼68,000 methylated regions per sample. While global CpG island (CGI) methylation was not differential between benign adjacent and cancer samples, overall promoter CGI methylation significantly increased from ∼12.6% in benign samples to 19.3% and 21.8% in localized and metastatic cancer tissues, respectively (P-value < 2 × 10?16). We found distinct patterns of promoter methylation around transcription start sites, where methylation occurred not only on the CGIs, but also on flanking regions and CGI sparse promoters. Among the 6691 methylated promoters in prostate tissues, 2481 differentially methylated regions (DMRs) are cancer-specific, including numerous novel DMRs. A novel cancer-specific DMR in the WFDC2 promoter showed frequent methylation in cancer (17/22 tissues, 6/6 cell lines), but not in the benign tissues (0/10) and normal PrEC cells. Integration of LNCaP DNA methylation and H3K4me3 data suggested an epigenetic mechanism for alternate transcription start site utilization, and these modifications segregated into distinct regions when present on the same promoter. Finally, we observed differences in repeat element methylation, particularly LINE-1, between ERG gene fusion-positive and -negative cancers, and we confirmed this observation using pyrosequencing on a tissue panel. This comprehensive methylome map will further our understanding of epigenetic regulation in prostate cancer progression.


Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer


Jung H. Kim,1,11 Saravana M. Dhanasekaran,1,2,11 John R. Prensner,1 Xuhong Cao,1 Daniel Robinson,1 Shanker Kalyana-Sundaram,1,3 Christina Huang,1 Sunita Shankar,1 Xiaojun Jing,1 Matthew Iyer,1 Ming Hu,4,12 Lee Sam,1,2 Catherine Grasso,1 Christopher A. Maher,1,2,5 Nallasivam Palanisamy,1 Rohit Mehra,1 Hal D. Kominsky,1 Javed Siddiqui,1 Jindan Yu,6 Zhaohui S. Qin,7 and Arul M. Chinnaiyan1,2,5,8,9,10,13

Publish date

2011 Jul;




The epidemiology and risk factors for hepatitis C virus (HCV) infection in Rwanda are not well known; however, this information is crucial to shaping the country’s public health approach to hepatitis C control.

A HCV screening campaign was conducted in the general population in 24 districts previously identified to have a high HCV disease burden. At the time of sample collection, sociodemographic information and self-reported risk factors were collected. Bivariate and multivariate logistic regressions were conducted to assess risk factors independently associated with hepatitis C antibodies (HCVAb) seroprevalence.

Out of a total of 326,263 individuals screened for HCVAb, 22,183 (6.8%) were positive. In multivariate analysis, risk factors identified as statistically associated with HCVAb Seroprevalence include history of traditional operation or scarification (OR = 1.09, 95% CI: 1.05-1.14), presence of viral hepatitis in the family (OR = 1.27, 95% CI: 1.15-1.40), widowed or separated/divorced (OR = 1.36, 95% CI: 1.26-1.47), Southern province (OR = 1.98, 95% CI: 1.88-2.08) and aged 65 years and older (OR = 4.86, 95% CI: 4.62-5.11). Ubudehe category 3 (OR = 0.97, 95% CI: 0.93-1.01) and participants using RAMA (Health insurances for employees of public and private sectors) insurance (OR = 0.76, 95% CI: 0.70-0.85) had lower odds of HCV seroprevalence.

Our findings provide important information for Rwanda’s strategy on prevention and case-finding. Future prevention interventions should aim to reduce transmission through targeted messaging around traditional healing practices and case-finding targeting individuals with a history of exposure or advanced age.


Viral hepatitis C, Risk factors, Rwanda


Risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program


Jean Damascene Makuza,corresponding author1 Carol Y. Liu,2 Corneille Killy Ntihabose,1 Donatha Dushimiyimana,1 Sabine Umuraza,2 Marie Paul Nisingizwe,3 Justine Umutesi,1 Janvier Serumondo,1 Soline Dusabeyesu Mugeni,2 Muhamed Semakula,1 Neil Gupta,4 Margaret Hellard,5 and Sabin Nsanzimana1

Publish date


Description :